496 related articles for article (PubMed ID: 18695440)
21. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
22. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.
Blankenship JC; Tasissa G; O'Shea JC; Iliadis EA; Bachour FA; Cohen DJ; Lui HK; Mann T; Cohen E; Tcheng JE;
J Am Coll Cardiol; 2001 Sep; 38(3):653-8. PubMed ID: 11527612
[TBL] [Abstract][Full Text] [Related]
23. Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).
Labinaz M; Madan M; O'Shea JO; Kilaru R; Chin W; Pieper K; McGuire DK; Saucedo JF; Talley JD; Lui H; Kitt MM; Califf RM; Tcheng JT;
Am J Cardiol; 2002 Sep; 90(6):585-90. PubMed ID: 12231081
[TBL] [Abstract][Full Text] [Related]
24. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
[TBL] [Abstract][Full Text] [Related]
25. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
[TBL] [Abstract][Full Text] [Related]
26. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.
Fischell TA; Attia T; Rane S; Salman W
J Invasive Cardiol; 2006 Oct; 18(10):487-91. PubMed ID: 17042093
[TBL] [Abstract][Full Text] [Related]
27. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
[TBL] [Abstract][Full Text] [Related]
28. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
Byrne RA; Schulz S; Mehilli J; Iijima R; Massberg S; Neumann FJ; ten Berg JM; Schömig A; Kastrati A;
Am Heart J; 2009 Apr; 157(4):620-4.e2. PubMed ID: 19332187
[TBL] [Abstract][Full Text] [Related]
29. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
30. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
31. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
PRICE Investigators
Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
[TBL] [Abstract][Full Text] [Related]
32. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
[TBL] [Abstract][Full Text] [Related]
33. Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents.
Nikolsky E; Holmes DR; Mehran R; Dangas G; Schampaert E; Morice MC; Schofer J; Sousa JE; Fahy M; Na Y; Donohoe DJ; Moses JW; Leon MB
Catheter Cardiovasc Interv; 2008 Jun; 71(7):896-906. PubMed ID: 18498145
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial).
Valencia R; Price MJ; Sawhney N; Lee SS; Wong GB; Gollapudi RR; Banares M; Schatz RA; Teirstein PS
Am J Cardiol; 2007 Oct; 100(7):1099-102. PubMed ID: 17884370
[TBL] [Abstract][Full Text] [Related]
35. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
36. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F
J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
[TBL] [Abstract][Full Text] [Related]
37. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
Capuano C; Sesana M; Leonzi O; Cuccia C
J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
[TBL] [Abstract][Full Text] [Related]
39. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
Plosker GL; Ibbotson T
Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
[TBL] [Abstract][Full Text] [Related]
40. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
